TD Cowen Maintains Buy on Biogen, Raises Price Target to $250
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.